Advertisement
Advertisement
MXCT
MaxCyte, Inc. Common Stock
0.85
USDSponsored
-0.04
-4.11%
Apr 15, 15:59 UTC -4
Closed
After-Market
0.84
-0.01
-0.97%
MXCT Earnings Reports
Positive Surprise Ratio
MXCT beat 16 of 19 last estimates.
84%
Next Report
Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
$7.44M
/-$0.08
Implied change from Q4 25 (Revenue/ EPS)
+1.98%
/+33.33%
Implied change from Q1 25 (Revenue/ EPS)
-28.35%
/-20.00%
MaxCyte, Inc. Common Stock earnings per share and revenue
On Mar 24, 2026, MXCT reported earnings of -0.06 USD per share (EPS) for Q4 25, beating the estimate of -0.08 USD, resulting in a 26.47% surprise. Revenue reached 7.30 million, compared to an expected 9.59 million, with a -23.91% difference. The market reacted with a -3.68% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.08 USD, with revenue projected to reach 7.44 million USD, implying an increase of 33.33% EPS, and increase of 1.98% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Nurix Therapeutics, Inc. Common stock
Report Date
Apr 08, 2026 For Q1 26
Estimate
-$0.76
Actual
-$0.79
Surprise
-2.68%
NovaBridge Biosciences - ADR
Report Date
Apr 07, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.28
Surprise
-421.58%
Scilex Holding Company Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$0.47
Actual
-$2.21
Surprise
-360.99%
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
Quince Therapeutics, Inc. Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$1.92
Actual
-$7.10
Surprise
-268.68%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
FAQ
What were MaxCyte, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, MaxCyte, Inc. Common Stock reported EPS of -$0.06, beating estimates by 26.47%, and revenue of $7.30M, -23.91% below expectations.
How did the market react to MaxCyte, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -3.68%, changed from $1.36 before the earnings release to $1.31 the day after.
When is MaxCyte, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 13, 2026.
What are the forecasts for MaxCyte, Inc. Common Stock's next earnings report?
Based on 7
analysts, MaxCyte, Inc. Common Stock is expected to report EPS of -$0.08 and revenue of $7.44M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement